Semaglutide and the clinical evidence

Semaglutide activates the receptor for glucagon-like peptide-1, or GLP-1, a hormone involved in appetite and blood-sugar control. A receptor is a protein that receives a chemical signal. Semaglutide can reduce food intake, support glucose-dependent insulin release, and slow stomach emptying. Glucose-dependent means the effect varies with the amount of sugar in the blood.

Semaglutide is the ingredient in prescription medicines including Ozempic and Wegovy. Those names refer to particular approved products, whose uses and formulations matter. They do not make every preparation containing semaglutide equivalent. A review of semaglutide safety explains the link between its biological effects and its common gastrointestinal adverse effects.

The STEP 1 trial studied adults with overweight or obesity who did not have diabetes. At 68 weeks, average body-weight change was about a 15% reduction with semaglutide and about a 2% reduction with placebo. Participants also received a lifestyle intervention. These are group averages, not a forecast for an individual.

The trial provides evidence for weight management in the population it studied. It does not show that every person will reach that average or tolerate the medicine. It also cannot establish equivalent effects for a different preparation, route, or schedule. A useful account keeps the trial’s conditions attached to the result rather than reducing the study to a single percentage.

The SELECT trial studied adults with established cardiovascular disease and overweight or obesity, without diabetes. Semaglutide reduced the combined risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke compared with placebo. The relative reduction was 20%. This is a change relative to the comparison group’s risk, not a 20-percentage-point fall in every participant’s risk.

The FLOW trial asked a different question in people with type 2 diabetes and chronic kidney disease. It found a lower risk of a combined outcome that included kidney failure, a major decline in kidney function, or death from kidney or cardiovascular causes with semaglutide. The population and outcome differ from SELECT and STEP 1. The results support specific clinical uses; they are not evidence of general protection in every otherwise healthy adult.

Different studies can produce different weight changes because they involve different people, follow-up periods, and treatment conditions. A direct comparison is usually more informative than placing unrelated trial averages side by side. In the SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide in adults with obesity over 72 weeks.

That result concerns a particular comparison and outcome. It does not rank either medicine for every person or replace the need to consider adverse effects and health history. Nor does it say anything about BPC-157 or MOTS-c, which lack a comparable body of large human treatment trials in the research covered here.

Nausea, vomiting, diarrhea, and constipation are prominent adverse effects in the safety review. They are often more noticeable while treatment is being increased. Some participants stop treatment because of adverse effects. A meaningful description of a treatment includes that experience alongside average benefits.

Gallbladder disease is another recognized concern. Pancreatitis, inflammation of the pancreas, is a warning associated with the drug class. In people with diabetes and existing diabetic eye disease, rapid improvement in blood sugar can be associated with worsening eye complications. These risks need their own clinical assessment; a favorable average trial result does not erase them.

Semaglutide labeling includes a thyroid C-cell tumor warning based on rodent findings and contraindications involving medullary thyroid carcinoma or multiple endocrine neoplasia type 2. The rodent finding does not establish the same cancer outcome in humans. Pregnancy and plans for pregnancy also affect prescribing decisions. A general reading guide cannot resolve these questions for a person.

FDA approval applies to a specific medicine and its authorized uses. Compounded semaglutide is not FDA-approved, even though the ingredient also appears in approved medicines. Evidence about an approved study product cannot verify the concentration, identity, or quality of a different preparation.

Prescription decisions involve the reason for treatment, other medicines, medical history, and the exact product. This page gives no personal dose or switching schedule. The questions page explains why research findings and access claims need separate evaluation, while the references link directly to the publications discussed here.